Skip to main content
Bloomberg Law

Drug, Device Manufacturers to Face Hill Scrutiny in 2019

January 8, 2019
Authors
Jaime L.M. Jones
Combating high drug and device prices is a bipartisan goal in Congress, and House Democrats in control of key oversight committees have made clear their plans to pursue investigations putting pharma CEOs under scrutiny. Manufacturers need to prep now to explain policies and prepare for public relations issues.
View Article

Contacts

Jones, Jaime L.M.
合伙人律师

Capabilities

Suggested News & Insights

Sidley Healthcare Investment Conference 2026Tuesday, September 22, 2026
活动
June DOJ/SBA FCA Settlement Highlights Continued Focus on Contractor ComplianceJuly 15, 2026
Original Source
OIG Signals Further Support for Manufacturer-Sponsored Testing Programs with Fourth Favorable Advisory OpinionJuly 8, 2026
Global Life Sciences Update
Texas Supreme Court Imposes Materiality Requirement on Texas Healthcare Fraud Omissions ClaimsJuly 7, 2026
Original Source
U.S. Clinical Trials: Federal Government Considers Safe Harbors to Encourage Enrollment and RetentionJuly 7, 2026
Global Life Sciences Update
Texas AG Secures Nearly $34 Million Settlement with Pharmaceutical Company, Reinforcing Active Ongoing THFPA EnforcementJuly 6, 2026
Original Source